Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Hypnotics Stories

2012-05-08 02:28:27

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- The new prescription sleep aid Intermezzo (zolpidem tartrate) sublingual tablet CIV is the first and only prescription sleep aid approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep, and the patient has at least four hours of bedtime remaining before the planned time of waking. Intermezzo has gender-specific dosing (1.75 mg for adult...

2012-04-23 03:13:35

Tokyo, Apr 17, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the insomnia treatment Lunesta(R) (eszopiclone) in Japan on April 18.Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc.; currently a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd.), is the first non-benzodiazepine type GABAA agonist to be launched in Japan in 12 years, and is believed to enhance GABA activity while exerting hypnotic...

2012-04-05 02:23:45

POINT RICHMOND, Calif., April 5, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that Intermezzo® (zolpidem tartrate) sublingual tablet CIV is now available by prescription in 1.75 mg and 3.5 mg dosage strengths in retail pharmacies nationwide. Intermezzo is the first and only prescription sleep aid approved for middle-of-the-night dosing, and should only be taken once per night in bed, as needed, when a patient wakes up in the middle of...

2012-04-05 02:23:40

STAMFORD, Conn., April 5, 2012 /PRNewswire/ -- Purdue Pharma L.P. announced today that Intermezzo(®) (zolpidem tartrate) sublingual tablet CIV is now available in 1.75 mg and 3.5 mg dosage strengths by prescription in retail pharmacies nationwide. Intermezzo is the first and only prescription sleep aid approved for middle-of-the-night dosing, and should only be taken once per night in bed, as needed, when a patient wakes up in the middle of the night and has difficulty returning to sleep....

2012-04-02 06:27:00

CHICAGO, April 2, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AstraZeneca (NYSE: AZN), Teva Pharmaceuticals Limited (Nasdaq: TEVA), Mylan Inc. (Nasdaq: MYL), Dr Reddy's Laboratories (NYSE: RDY) and POSCO (NYSE: PKX). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get...

2012-03-28 02:24:25

PITTSBURGH, March 28, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quetiapine Fumarate Tablets, 25 mg. This product is the generic version of AstraZeneca's Seroquel®, which is an atypical antipsychotic medication indicated for the treatment of schizophrenia, and for the treatment of acute manic...

Sleeping Pills Linked To Increased Risk Of Death
2012-02-28 11:03:43

A new study finds that people who take certain commonly prescribed sleeping pills have a five-fold increased risk of death, even among those taking fewer than 18 doses a year. And these drugs are also linked to a significantly increased risk of cancer among those taking high doses, the study, published in the journal BMJ Open, shows. The study, analyzing 10,500 people who took a wide-range of sleeping pills including zolpidem, diazepam and tamazepam, found that the top third of sleeping...

2012-02-27 18:53:00

SAN DIEGO, Feb 27, 2012 /PRNewswire/ -- People are relying on sleeping pills more than ever to get a good night's rest, but a new study by Scripps Clinic researchers links the medications to a 4.6 times higher risk of death and a significant increase in cancer cases among regular pill users. The results, published today by the open-access online journal BMJ Open, cast a shadow over a growing segment of the pharmaceutical industry that expanded by 23 percent in the United States from 2006 to...

2012-02-20 07:20:00

ATLANTA, Feb. 20, 2012 /PRNewswire/ -- The circumstances of Whitney Houston's demise have dominated headlines and search trends since news outlets first reported of her death. Her struggle with addiction was covered extensively by the media, and even discussed candidly by Houston herself during several high-profile interviews. Though toxicology reports needed for definitive answers have yet to be released, there has been no delay in rumors and speculation regarding what drugs may have been...

2012-02-16 14:57:15

Drug delivery directly into muscle using an autoinjector is faster and may be more effective in stopping prolonged seizures, according to a study sponsored by the National Institutes of Health and conducted by a Wayne State University School of Medicine researcher. The trial compared the effectiveness of two Federal Drug Administration-approved anti-seizure medications and how they are administered to patients suffering prolonged seizures before they arrive at hospitals. The Rapid...